A Breath Biomarker Company
When lung infections are on the line, every minute counts.
The rapid Avisa BreathTest™ can detect lung bacterial infection in 10 minutes.
COVID-19 Pandemic Heightens Need for Pulmonary Diagnostic Innovation
50% of Covid-19 deaths are co-infected with bacterial pneumonia
The only test that can differentiate a virulent bacterial infection from strep pneumonia and viral lung infection.
Value-Based, Cost Advantaged Product is a Win for Patient, Doctor, Hospital and PayerLearn More About Clinical Applications
|Turnaround Time < 10 minutes|
|Non-Sputum Producing Patients|
Disease prevalence estimates obtained from literature
Including US, Europe, Japan, China
Indications for use tested in interviews with physicians, respiratory therapists, insurance plan chief medical officers and Avisa medical advisory board.